Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-04-26 | Kiniksa Pharmaceuticals, Ltd. | Ragosa Mark
(CHIEF FINANCIAL OFFICER) |
F | Class A Common Share | D | 509 | $17.88 - $17.88 | $9,100 |
| 2024-04-08 | Kiniksa Pharmaceuticals, Ltd. | Patel Sanj K
(CHAIRMAN & CEO) |
F | Class A Common Share | D | 4075 | $17.90 - $17.90 | $72,942 |
| 2024-04-08 | Kiniksa Pharmaceuticals, Ltd. | Paolini John F.
(CHIEF MEDICAL OFFICER) |
F | Class A Common Share | D | 733 | $17.90 - $17.90 | $13,120 |
| 2024-04-08 | Kiniksa Pharmaceuticals, Ltd. | Ragosa Mark
(CHIEF FINANCIAL OFFICER) |
F | Class A Common Share | D | 791 | $17.90 - $17.90 | $14,158 |
| 2024-04-08 | Kiniksa Pharmaceuticals, Ltd. | Moat Ross
(CHIEF COMMERCIAL OFFICER) |
F | Class A Common Share | D | 1353 | $17.90 - $17.90 | $24,218 |
| 2024-04-08 | Kiniksa Pharmaceuticals, Ltd. | Megna Michael R
(CHIEF ACCOUNTING OFFICER) |
F | Class A Common Share | D | 1666 | $17.90 - $17.90 | $29,821 |
| 2024-04-08 | Kiniksa Pharmaceuticals, Ltd. | Tessari Eben
(CHIEF OPERATING OFFICER) |
F | Class A Common Share | D | 801 | $17.90 - $17.90 | $14,337 |
| 2024-04-01 | Kiniksa Pharmaceuticals, Ltd. | Ragosa Mark
(CHIEF FINANCIAL OFFICER) |
F | Class A Common Share | D | 514 | $19.70 - $19.70 | $10,125 |
| 2024-04-01 | Kiniksa Pharmaceuticals, Ltd. | Paolini John F.
(CHIEF MEDICAL OFFICER) |
F | Class A Common Share | D | 477 | $19.70 - $19.70 | $9,396 |
| 2024-03-07 | Kiniksa Pharmaceuticals, Ltd. | Patel Sanj K
(CHAIRMAN & CEO) |
S | Class A Common Share | D | 65012 | $21.02 - $21.02 | $1,366,552 |
| 2024-03-04 | Kiniksa Pharmaceuticals, Ltd. | Patel Sanj K
(CHAIRMAN & CEO) |
S | Class A Common Share | D | 18324 | $21.00 - $22.00 | $391,055 |
| 2024-02-28 | Kiniksa Pharmaceuticals, Ltd. | Megna Michael R
(CHIEF ACCOUNTING OFFICER) |
S | Class A Common Share | D | 14785 | $21.45 - $21.79 | $318,880 |
| 2024-02-28 | Kiniksa Pharmaceuticals, Ltd. | Megna Michael R
(CHIEF ACCOUNTING OFFICER) |
M | Class A Common Share | A | 14785 | $8.83 - $13.88 | $150,821 |
| 2024-01-15 | Kiniksa Pharmaceuticals, Ltd. | Megna Michael R
(CHIEF ACCOUNTING OFFICER) |
A | Class A Common Share | A | 583 | $12.35 - $12.35 | $7,200 |
| 2024-02-27 | Kiniksa Pharmaceuticals, Ltd. | Paolini John F.
(CHIEF MEDICAL OFFICER) |
S | Class A Common Share | D | 10156 | $21.03 - $21.03 | $213,580 |
| 2024-02-27 | Kiniksa Pharmaceuticals, Ltd. | Paolini John F.
(CHIEF MEDICAL OFFICER) |
M | Class A Common Share | A | 10156 | $1.86 - $1.86 | $18,890 |
| 2024-01-03 | Kiniksa Pharmaceuticals, Ltd. | Ragosa Mark
(CHIEF FINANCIAL OFFICER) |
S | Class A Common Share | D | 12000 | $20.00 - $20.00 | $240,000 |
| 2024-01-03 | Kiniksa Pharmaceuticals, Ltd. | Ragosa Mark
(CHIEF FINANCIAL OFFICER) |
M | Class A Common Share | A | 12000 | $8.83 - $8.83 | $105,960 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |